TIXiMED
Private Company
Total funding raised: $2.5M
Overview
TIXiMED is pioneering a novel therapeutic approach for diabetes and related metabolic disorders by targeting the protein TXNIP, a key regulator of pancreatic beta-cell function and glucagon secretion. Its lead candidate, TIX100, is an oral small molecule that has successfully completed a Phase 1 single ascending dose study and shows promise in addressing significant unmet needs, including a potential oral therapy for Type 1 Diabetes and a treatment for MASLD. The company leverages strong academic origins, exclusive intellectual property, and a seasoned leadership team with deep expertise in diabetes drug development and commercialization.
Technology Platform
Oral small molecule inhibitors targeting TXNIP (thioredoxin-interacting protein) to protect pancreatic beta-cells, preserve insulin production, and normalize glucagon secretion in metabolic diseases.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
In Type 1 Diabetes, TIX100 would compete against insulin and adjunctive non-insulin therapies (e.g., SGLT inhibitors used off-label), but faces no direct oral disease-modifying competitor. In Type 2 Diabetes and MASLD/MASH, it will compete with numerous established and novel drug classes, including GLP-1 agonists, SGLT2 inhibitors, and emerging MASH therapies, requiring clear differentiation on efficacy, safety, or mechanism.